AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03238716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NM Re-ed
Description: sEMG targeting type I slow-twitch fibers and type II fast-twitch fibers. Type I fibers maintain continuous muscle activity over prolonged periods of time; therefore, training of type I fibers will be achieved through endurance and repetition training of the pelvic floor muscles. Type II fibers are recruited during sudden increases in intra-abdominal pressure, and these fibers will be recruited with The Knack training. The Knack is a term created to use rhythm or timing to the pelvic floor. Neuromuscular re-education will be performed during the first treatment, but it will be performed as needed on subsequent treatments.
Study NCT03238716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at > 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).
Study NCT03238716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at > 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).
Study NCT01404039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Learning
Description: Subject will have to draw a set of shapes and words during 20 minutes.
Study NCT01404039 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motor Learning
Description: Subject will have to draw a set of shapes and words during 20 minutes.
Study NCT01404039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatosensory Learning
Description: Subjects will perform a learning task involving sensory activation of the hand. The task will consist of learning letters of Braille.
Study NCT01404039 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Somatosensory Learning
Description: Subjects will perform a learning task involving sensory activation of the hand. The task will consist of learning letters of Braille.
Study NCT01404039 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Observational Task
Description: Subjects will watch a 10 second video of a right-handed person performing movements of their left index finger. Subjects will be instructed to watch the video without any other specific instruction.
Study NCT01404039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observational Task
Description: Subjects will watch a 10 second video of a right-handed person performing movements of their left index finger. Subjects will be instructed to watch the video without any other specific instruction.
Study NCT01404039 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mental Imagery
Description: Subjects will be asked to perform mental imagery of motor practice - finger movements of the left hand for 10 minutes.
Study NCT01404039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery
Description: Subjects will be asked to perform mental imagery of motor practice - finger movements of the left hand for 10 minutes.
Study NCT01404039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Subjects will undergo active and sham tDCS stimulation in a randomized and counterbalanced order. During both active and sham stimulation, we will use electrodes of 35cm\^2, intensity of 2mA for a duration of 20 minutes. The anode electrode will be placed over the right primary motor cortex (M1) and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be on for the duration of 20 minutes. For sham stimulation, the current will ramp up, and then down again for 30 seconds to simulate the sensation of active tDCS.
Study NCT01404039 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Subjects will undergo active and sham tDCS stimulation in a randomized and counterbalanced order. During both active and sham stimulation, we will use electrodes of 35cm\^2, intensity of 2mA for a duration of 20 minutes. The anode electrode will be placed over the right primary motor cortex (M1) and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be on for the duration of 20 minutes. For sham stimulation, the current will ramp up, and then down again for 30 seconds to simulate the sensation of active tDCS.
Study NCT02452307 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine
Description: subcutaneous
Study NCT02452307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Description: subcutaneous
Study NCT02452307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony stimulating factor (GM-CSF)
Description: intradermal
Study NCT02452307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: epicutaneous
Study NCT02452307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA
Description: subcutaneous
Study NCT02452307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protamin
Description: subcutaneous
Study NCT02452307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local hyperthermia
Study NCT01579903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moroctocog alfa (AF-CC)
Description: Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes
Study NCT01579903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moroctocog alfa (AF-CC)
Description: Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)
Study NCT00178477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI with breath-holding
Description: Breath holding for diminished tumor motion.
Study NCT00670553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Study NCT01848158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Patients randomized to active treatment will receive acupuncture treatment with press needles (small acupuncture needles manufactured with attached bandage that makes the needle flush with skin) at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a seed magnet at ear shen men position for 4 hours on treatment days.
Study NCT01848158 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Patients randomized to sham treatment will receive sham acupuncture with similarly appearing bandages placed without press needles attached at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a similarly appearing bandage without seed magnet underneath at ear shen men position for 4 hours on treatment days.
Study NCT01417546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHS-IL-12
Description: NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
Study NCT00786292 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assisted mechanical ventilation
Description: Patients will be mechanically ventilated with noisy PSV and PSV in random sequence
Study NCT04434079 — intervention group
Intervention type: OTHER
Intervention: Regular critical care
Description: Clinical demographic data, daily and cumulative FB (input minus output) with and without insensible fluid losses, and daily and total BW changes are recorded, as well as survival outcome.
Study NCT02335619 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early palliative care
Study NCT02467179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amigo™ Robotic Catheter Manipulation
Description: Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to robotic catheter manipulation.
Study NCT02467179 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Catheter Manipulation
Description: Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to manual catheter manipulation.
Study NCT01502748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endovascular sampling
Description: Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations: withdrawal of 3ml of blood from vasculature distal to the occlusive thrombus
Study NCT02254811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: transfer of healthy human gut bacteria to restore the microbiome
Study NCT02654886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months~Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months
Study NCT01866540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUENZ
Description: live attenuated influenza vaccine
Study NCT00261365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
Study NCT00261365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
Study NCT03533673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACTUS-101
Description: Adeno-associated virus serotype 8 carrying the human GAA gene under the control of the LSP promoter.
Study NCT03154866 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus kefiri LKF01 DSM32079
Description: Lactobacillus kefiri LKF01 DSM32079 in drop formulation. 5 drop/daily for 21 days
Study NCT03154866 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in drop formulation. 5 drop/daily for 21 days
Study NCT02250742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dry needling
Description: Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.
Study NCT02250742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.
Study NCT03293602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F-MISO PET imaging
Description: F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
Study NCT00018148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nortriptyline
Description: Dose titrated to 75 mg daily as tolerated combined with transdermal nicotine 21 mg
Study NCT00018148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal nicotine
Description: Transdermal nicotine 21 mg, titrated down plus placebo
Study NCT01329315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BMI-T
Description: Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
Study NCT01329315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BMI-C
Description: Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
Study NCT00754702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity
Study NCT00754702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity
Study NCT03335384 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Esophageal Balloon
Description: Small flexible catheter with deflated balloon at distal end to be inserted into the esophagus through the nose
Study NCT03335384 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Gastric Balloon
Description: Small flexible catheter with deflated balloon at distal end to be inserted into the stomach through the nose
Study NCT03335384 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasal Pressure Transducer
Description: Pressure transducer inserted into nasal plug
Study NCT01279434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E plus Pentoxiphyllin
Description: Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
Study NCT01279434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E 400 mg BD daily for 12 months
Study NCT01273766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: Given orally
Study NCT01273766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01273766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT01608763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Your Drinking (CYD) personalized feedback intervention
Description: The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
Study NCT01033981 — intervention group
Intervention type: DRUG
Intervention: Sunitinib
Description: Treatment for mRCC as indication approved and physician criterium
Study NCT02707627 — intervention group
Intervention type: DEVICE
Intervention: Laser Therapy
Description: Laser therapy is a technology that can be used to treat hypertrophic burn scars.
Study NCT01621737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 42 IU BID for six weeks
Study NCT02348177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir with ritonavir in 1:1 ratio
Description: During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio
Study NCT02348177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 4:1
Description: This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped
Study NCT02253914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, solution
Study NCT02253914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, tablet
Study NCT02253914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02253914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00379535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: potassium iodide
Description: per os
Study NCT00379535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: per os
Study NCT00383552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID
Description: MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
Study NCT00383552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate MDI (MF MDI)
Description: MF 100 mcg via metered dose inhaler twice daily for 26 weeks
Study NCT00383552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate 10 mcg
Description: F via metered dose inhaler 10 mcg twice a day for 26 weeks
Study NCT00383552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo metered dose inhaler twice a day for 26 weeks
Study NCT04739644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Specific wrist rehabilitation by WRISTBOT device
Description: The WRISTBOT is a fully backdrivable manipulandum that allows for movements along its 3 Degrees of Freedom (DoFs) in a human-like Range Of Motion (ROM) of the wrist: 62° flexion/extension (FE), -40°/+45° in ulnar/radial deviation (RUD), and 60° pronation/supination (PS). In addition, the robot permits motions along planes that involve combined multi-DoFs movements. Mechanically, the robot was developed to have low values of inertia, emulating the fluency of natural movements. Each DOF is measured by high resolution incremental encoders and actuated by one brushless motor or two in case of the RUD planes, providing both gravity compensation and continuous torque values necessary to manipulate the human wrist joints. Depending on the torques exerted, the device can be used in either active or assistive/passive modality. The system is integrated with a Virtual Reality environment (VR), useful to provide a visual feedback to the user while he/she is requested to complete the tasks.
Study NCT04739644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specific wrist rehabilitation performed by the physiotherapist
Description: Passive, active and assisted mobilization
Study NCT04739644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General rehabilitation
Description: Exercise with elastic bands or weights, exercise of manipulation and dexterity, simulation of daily life activities supervised by the physiotherapist
Study NCT04739644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General rehabilitation
Description: Exercise with elastic bands or weights, exercise of manipulation and dexterity, simulation of daily life activities supervised by the physiotherapist
Study NCT03852602 — intervention group
Intervention type: DRUG
Intervention: Preemptive Analgesics
Description: Analgesic application15 minutes before the treatment
Study NCT03852602 — intervention group
Intervention type: DRUG
Intervention: Control
Description: Analgesic application15 minutes before the end of the treatment
Study NCT04819217 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Active bamboo charcoal
Description: During this 6 months' trial, eligible 120 patients with eGFR 15 \< eGFR \< 45 ml/min/1.73m2 and UACR > 100 mg/g will be enrolled and randomized into 4 groups. The patients in group 1 will receive CharXenPlus 4g (with ABC 2g) thrice daily + CharXprob 0.8 g once daily in the initial 3 months. Group 2 will receive CharXenPlus 4g thrice daily in the initial 3 months, and CharXprob 0.8 g once daily in the last 3 months. Group 3 will receive CharXprob 0.8 g once daily in the initial 3 months, and CharXenPlus 4g thrice daily in the last 3 months. Group 4 will only receive CharXprob 0.8 g once daily in the last 3 months.
Study NCT04819217 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotics
Description: Probiotics
Study NCT02994238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Health Management Sensor Platform
Description: The Propeller sensor monitors the use of inhaled medications, capturing the date, time, and number of uses. The sensor then transmits this information using Bluetooth to a paired smart phone or hub. Data can be uploaded to the caregiver's smart phone and to the patient's web portal, which their healthcare team will have access to help overall management.
Study NCT02172430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium powder inhalation capsules
Description: Powder inhalation via the HandiHaler® once daily
Study NCT02172430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tersigan®
Description: 2 puffs of oxitropium three times daily via MDI
Study NCT04521790 — intervention group
Intervention type: OTHER
Intervention: support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
Description: Treatment will be patient-tailored, integrating international guidelines recommendation and the experience of the center where enrollment takes place.